Emerging Therapies in Relapsing-Remitting Multiple Sclerosis

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|5|3|179-188

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.5, Iss.3, 2010-09, pp. : 179-188

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Teriflunomide for relapsing remitting multiple sclerosis

By  

PRESCRIBER, Vol. 26, Iss. 18, 2015-09 ,pp. : 11-14

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison

By Hutchinson Michael   Fox Robert J.   Havrdova Eva   Kurukulasuriya Nuwan C.   Sarda Sujata P.   Agarwal Sonalee   Siddiqui Mohd Kashif   Taneja Ankush   Deniz Baris  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 613-627

Informa Healthcare

Access to resources Recommend Favorite

The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis

By Namaka Mike   Pollitt-Smith Merinda   Gupta Aneri   Klowak Meghann   Vasconcelos Marcus   Turcotte Dana   Gong Yuewen   Melanson Maria  

Current Medical Research and Opinion, Vol. 22, Iss. 2, 2006-02 ,pp. : 223-239

Informa Healthcare

Access to resources Recommend Favorite

Assessment of new application system in Portuguese patients with relapsing-remitting multiple sclerosis

By de Sá J.   Urbano G.   Reis L.  

Current Medical Research and Opinion, Vol. 26, Iss. 9, 2010-09 ,pp. : 2237-2242

Informa Healthcare

Access to resources Recommend Favorite

Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

By  

ANNALS OF NEUROLOGY, Vol. 77, Iss. 3, 2015-03 ,pp. : 425-435

John Wiley & Sons Inc

Access to resources Recommend Favorite